Results 71 to 80 of about 6,415,892 (312)

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

open access: yesFEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill   +6 more
wiley   +1 more source

Additional file 1: of LRRK2 contributes to monocyte dysregulation in Parkinsonâ s disease

open access: yes, 2019
Supplementary materials and methods. (PDF 1185 kb)
Bliederhaeuser, Corinna   +11 more
openaire   +1 more source

Beyond the clinical aspects: the social implications of Parkinson’s disease

open access: yes, 2022
From a clinical standpoint, Parkinson’s disease (PD) is a severe, disabling neurodege-nerative disorder characterised by a progressive and chronic disturbance, mainly (though not exclusively) affecting movement control and balance (Poewe et al., 2017 ...
Lombi L.
core  

In silico and in vitro exploration of a tyrosinase for biocatalytic production of catechols

open access: yesFEBS Open Bio, EarlyView.
Tyrosinase from Ralstonia pseudosolanacearum is a promising biocatalyst for producing valuable catechols from monophenol substrates. This tyrosinase is uniquely suited to this due to its high monophenolase : diphenolase ratio. We combined in silico docking and in vivo kinetic characterisation of this tyrosinase with 11 industrially relevant monophenols,
James Britton   +6 more
wiley   +1 more source

Image-guided programming deep brain stimulation improves clinical outcomes in patients with Parkinson’s disease

open access: yesnpj Parkinson's Disease
Deep brain stimulation (DBS) is an effective treatment for patients with Parkinson’s disease (PD). However, some patients may not respond optimally to clinical programming adjustments.
Viviana Torres   +8 more
doaj   +1 more source

Axonal Modulation of Striatal Dopamine Release by Local γ-Aminobutyric Acid (GABA) Signalling

open access: yesCells, 2021
Striatal dopamine (DA) release is critical for motivated actions and reinforcement learning, and is locally influenced at the level of DA axons by other striatal neurotransmitters. Here, we review a wealth of historical and more recently refined evidence
Bradley M. Roberts   +2 more
doaj   +1 more source

Interaction- and asymmetry-aware facial blendshape analysis for objective quantification of Parkinsonian hypomimia

open access: yesnpj Parkinson's Disease
Reduced facial expressivity (hypomimia) is an early motor feature of Parkinson’s disease (PD), yet its assessment still relies on subjective, coarse-grained clinical scales.
Berkan Koyak   +13 more
doaj   +1 more source

Live Imaging of Axonal Transport in the Motor Neurons of Drosophila Larvae

open access: yesBio-Protocol, 2017
Axonal transport, which is composed of microtubules, motor proteins and a variety of types of cargo, is a prominent feature of neurons. Monitoring these molecular dynamics is important to understand the biological processes of neurons as well as ...
Tsuyoshi Inoshita   +2 more
doaj   +1 more source

Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism

open access: yesnpj Parkinson's Disease, 2022
Drug-induced parkinsonism (DIP) can be clinically indistinguishable from degenerative parkinsonism, and bedside assessments are needed to differentiate between these conditions. We examined 34 U.S.
Whitley W. Aamodt   +6 more
doaj   +1 more source

MOESM4 of A randomized controlled efficacy study of the Medido medication dispenser in Parkinsonâ s disease

open access: yes, 2019
Additional file 4. Table with secondary outcomes of PDQ-carer.
Hannink, K.   +8 more
openaire   +1 more source

Home - About - Disclaimer - Privacy